Literature DB >> 3017399

Antibody dependent cellular cytotoxicity against coronavirus 229E-infected cells.

M J Holmes, K A Callow, R A Childs, D A Tyrrell.   

Abstract

An antibody dependent cellular cytotoxic (ADCC) reaction was elicited using human mixed lymphocyte cultures against coronavirus 229E-infected C-16 cells. The response was assayed in microtitre plates by radioactive chromium release. Optimal killing of target cells was achieved using cells labelled 22 h after infection. A prozone was present and the optimal dilution of sera was invariably 1:200. The majority (70%) of sera tested gave a positive ADCC response. These included all sera judged positive by ELISA, but also some which were judged negative. Two experiments using purified IgG from serum which was ADCC and ELISA positive suggested that the response is mediated by an IgG antibody and that the prozone is due to a separate serum component.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3017399      PMCID： PMC2013047     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN： 0007-1021


  7 in total

1.  Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus.

Authors:  S L Shore; C M Black; F M Melewicz; P A Wood; A J Nahmias
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

2.  Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection.

Authors:  K A Callow
Journal:  J Hyg (Lond)       Date:  1985-08

3.  Intracellular development and mechanism of hemadsorption of a human coronavirus, OC43.

Authors:  R A Bucknall; A R Kalica; R M Chanock
Journal:  Proc Soc Exp Biol Med       Date:  1972-03

4.  Left ventricular function and rapid release of creatine kinase MB in acute myocardial infarction. Evidence for spontaneous reperfusion.

Authors:  L Ong; P Reiser; J Coromilas; L Scherr; J Morrison
Journal:  N Engl J Med       Date:  1983-07-07       Impact factor: 91.245

5.  Human monocyte-macrophage-mediated antibody-dependent cytotoxicity to herpes simplex virus-infected cells.

Authors:  S Kohl; S E Starr; J M oleske; S L Shore; R B Ashman; A J Nahmias
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

6.  Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells.

Authors:  J M Oleske; R B Ashman; S Kohl; S L Shore; S E Starr; P Wood; A J Nahmias
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

7.  Human neonatal and maternal monocyte-macrophage and lymphocyte-mediated antibody-dependent cytotoxicity to cells infected with herpes simplex.

Authors:  S Kohl; S S Shaban; S E Starr; P A Wood; A J Nahmias
Journal:  J Pediatr       Date:  1978-08       Impact factor: 4.406
  7 in total
  10 in total

1.  Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection.

Authors:  M J Koolen; M A Borst; M C Horzinek; W J Spaan
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation.

Authors:  Dieter Mielke; Sherry Stanfield-Oakley; Shalini Jha; Taylor Keyes; Adam Zalaquett; Brooke Dunn; Nicole Rodgers; Thomas Oguin; Greg D Sempowski; Raquel A Binder; Gregory C Gray; Shelly Karuna; Lawrence Corey; John Hural; Georgia D Tomaras; Justin Pollara; Guido Ferrari
Journal:  Cytometry A       Date:  2022-04-01       Impact factor: 4.714

3.  Antibody Attributes that Predict the Neutralization and Effector Function of Polyclonal Responses to SARS-CoV-2.

Authors:  Harini Natarajan; Shiwei Xu; Andrew R Crowley; Savannah E Butler; Joshua A Weiner; Evan M Bloch; Kirsten Littlefield; Sarah E Benner; Ruchee Shrestha; Olivia Ajayi; Wendy Wieland-Alter; David Sullivan; Shmuel Shoham; Thomas C Quinn; Arturo Casadevall; Andrew Pekosz; Andrew D Redd; Aaron A R Tobian; Ruth I Connor; Peter F Wright; Margaret E Ackerman
Journal:  medRxiv       Date:  2021-08-08

4.  Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics.

Authors:  Robert V House; Thomas A Broge; Todd J Suscovich; Doris M Snow; Milan T Tomic; Genevieve Nonet; Kamaljit Bajwa; Guangyu Zhu; Zachary Martinez; Kyal Hackett; Christopher G Earnhart; Nicole M Dorsey; Svetlana A Hopkins; Dalia S Natour; Heather D Davis; Michael S Anderson; Melicia R Gainey; Ronald R Cobb
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

5.  Some recent work at the Common Cold Unit, Salisbury.

Authors:  D A Tyrrell
Journal:  Infection       Date:  1988 Sep-Oct       Impact factor: 3.553

6.  Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.

Authors:  Harini Natarajan; Andrew R Crowley; Savannah E Butler; Aaron A R Tobian; Margaret E Ackerman; Shiwei Xu; Joshua A Weiner; Evan M Bloch; Kirsten Littlefield; Wendy Wieland-Alter; Ruth I Connor; Peter F Wright; Sarah E Benner; Tania S Bonny; Oliver Laeyendecker; David Sullivan; Shmuel Shoham; Thomas C Quinn; H Benjamin Larman; Arturo Casadevall; Andrew Pekosz; Andrew D Redd
Journal:  mBio       Date:  2021-04-20       Impact factor: 7.786

Review 7.  The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19.

Authors:  Arturo Casadevall; Liise-Anne Pirofski; Michael J Joyner
Journal:  mBio       Date:  2021-03-02       Impact factor: 7.867

8.  Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2.

Authors:  Harini Natarajan; Shiwei Xu; Andrew R Crowley; Savannah E Butler; Joshua A Weiner; Evan M Bloch; Kirsten Littlefield; Sarah E Benner; Ruchee Shrestha; Olivia Ajayi; Wendy Wieland-Alter; David Sullivan; Shmuel Shoham; Thomas C Quinn; Arturo Casadevall; Andrew Pekosz; Andrew D Redd; Aaron A R Tobian; Ruth I Connor; Peter F Wright; Margaret E Ackerman
Journal:  BMC Immunol       Date:  2022-02-16       Impact factor: 3.594

9.  SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy.

Authors:  Harini Natarajan; Andrew R Crowley; Savannah E Butler; Shiwei Xu; Joshua A Weiner; Evan M Bloch; Kirsten Littlefield; Wendy Wieland-Alter; Ruth I Connor; Peter F Wright; Sarah E Benner; Tania S Bonny; Oliver Laeyendecker; David J Sullivan; Shmuel Shoham; Thomas Quinn; H Benjamin Larman; Arturo Casadevall; Andrew Pekosz; Andrew Redd; Aaron Ar Tobian; Margaret E Ackerman
Journal:  medRxiv       Date:  2020-09-18

10.  Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.

Authors:  Victoria Roulstone; David Mansfield; Robert J Harris; Katie Twigger; Christine White; Johann de Bono; James Spicer; Sophia N Karagiannis; Richard Vile; Hardev Pandha; Alan Melcher; Kevin Harrington
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.